Breaking News Instant updates and real-time market news.

CDNA

CareDx

$3.55

-0.21 (-5.59%)

13:07
10/03/16
10/03
13:07
10/03/16
13:07

CareDx calls for reversal of reimbursement cut to diagnostic test

CareDx said this morning it is calling for a reversal of a decision by the Centers for Medicare & Medicaid Services to reduce reimbursement for its diagnostic test AlloMap -- the only FDA-cleared blood test to monitor heart transplant patients for rejection, and the only alternative to more costly and invasive biopsies, according to the company. "This decision is unwise, unfair, and misaligned with President Obama's Precision Medicine Initiative," remarked CEO Peter Maag, who called on CMS to reconsider and reverse its proposed 32% decrease in reimbursement -- from $2,821 to $1,920.93. Maag expressed confidence that CMS will reconsider the decision, saying, "The transplant community of providers, patients, and caregivers will continue to engage with CMS during the reconsideration process." If left unchanged, the new rate would take effect as of January 1, 2017. "This process is only being used due to the delay in implementation of PAMA, where this type of reduction in reimbursement would not be permitted... AlloMap is used in the vast majority of heart transplant centers nationwide, with more than 75,000 commercial tests performed to date. During this time CareDx has never increased the price of AlloMap. CareDx has continued to further invest in improvements of the technology and new transplant services despite not having made a profit on AlloMap," the company added.

  • 15

    Nov

CDNA CareDx
$3.55

-0.21 (-5.59%)

06/13/16
LEER
06/13/16
NO CHANGE
LEER
CMS price proposals for diagnostic tests a negative for most, says Leerink
Leerink analyst Dan Leonard expects several diagnostics stocks to underperform following proposed price cuts or low initial reimbursement rates by the Centers for Medicare and Medicaid Services, or CMS, for diagnostic tests. If finalized, the preliminary pricing would negatively impact CareDx (CDNA), Veracyte (VCYT), and InVitae (NVTA), the analyst tells investors in a research note, adding that he also sees an indirect negative read-through for Illumina (ILMN).
06/13/16
CANT
06/13/16
NO CHANGE
Target $13
CANT
Buy
Cantor sees 'flawed methodology' with new CMS rates
Cantor Fitzgerald analyst Bryan Brokmeier says shares of Veracyte (VCYT) may be under pressure this morning following Friday's release of a proposed gapfill Medicare reimbursement rate reduction on the company's Afirma GEC. Along with the 30% reduction on Afirma's GEC, the release from the Centers for Medicare and Medicaid Services resets rates on 15 other molecular diagnostic tests, including reductions in CareDx's (CNDA) AlloMap, which is down 74%, Genomic Health's (GHDX) Oncotype Dx Colon, which is down 73%, and Rosetta Genomics' (ROSG) Cancer Origin Test, which is down 57%, Brokmeier tells investors in a research note. The analyst, however, believes the preliminary proposed gapfill rate is based on a "flawed methodology" because it is the median proposed rate submitted by all Medicare Administrative Contractors, including those that have little or no experience administering claims on these tests, Brokmeier contends. He points out that Medicare represents approximately 20% of Afirma GEC test volume for Veracyte. Based on 2015 volume, the 30% Medicare rate reduction for Afirma would reduce total revenues by $3.7M or 7.5%, he adds. The analyst keeps a Buy rating on Veracyte with a $13 price target.
06/20/16
PIPR
06/20/16
NO CHANGE
PIPR
Final PAMA rule better than expected, says Piper Jaffray
Piper Jaffray analyst William Quirk says the final Protecting Access to Medicare Act published Friday by Centers for Medicare & Medicaid Services is better than expected. PAMA is delayed until 2018 from 2017 as expected, Quirk tells investors in a research note. Hospital labs will be required to submit private payer rates to CMS, a positive relative to prior expectations, the analyst notes. He views the decision as beneficial for Quest Diagnostics (DGX) and LabCorp (LH). Further, CMS will require labs to submit only in-network rates and out-of-network "final" rates, which is a positive for specialty labs who have in-network rates at or above Medicare including CareDx (CDNA), Genomic Health (GHDX), Myriad Genetics (MYGN), Oxford Immunotec (OXFD) and Veracyte (VCYT), Quirk writes.
07/07/16
PIPR
07/07/16
NO CHANGE
PIPR
New FDA recommendation positive for lab companies, says Piper Jaffray
Piper Jaffray analyst William Quirk says that the FDA has issued draft guidance to streamline its approval process for next-generation sequencing, or NGS, germline tests, which could be a substitute for a Premarket Notification or 510k. The analyst believes streamlined regulatory approaches for NGS tests are a positive for labs with NGS laboratory-developed tests such as CareDx (CDNA), Quest Diagnostics (DGX), Genomic Health (GHDX), LabCorp (LH), Myriad Genetics (MYGN), Natera (NTRA), Oxford Immunotec (OXFD), Sequenom (SQNM), Trovagene (TROV), and Veracyte (VCYT).

TODAY'S FREE FLY STORIES

15:10
12/07/16
12/07
15:10
12/07/16
15:10
General news
U.S. consumer credit rose $16.0 B in October »

U.S. consumer credit rose…

COST

Costco

$151.01

-0.76 (-0.50%)

15:04
12/07/16
12/07
15:04
12/07/16
15:04
Options
Costco options imply 4.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCO

Columbus McKinnon

$27.59

1.07 (4.03%)

15:03
12/07/16
12/07
15:03
12/07/16
15:03
Downgrade
Columbus McKinnon rating change  »

Follow-up: Columbus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

OTTR

Otter Tail

$38.90

0.1 (0.26%)

15:01
12/07/16
12/07
15:01
12/07/16
15:01
Initiation
Otter Tail initiated  »

Otter Tail initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:01
12/07/16
12/07
15:01
12/07/16
15:01
General news
Consumer Credit data reported »

October Consumer Credit…

WDC

Western Digital

$63.85

1.76 (2.83%)

15:00
12/07/16
12/07
15:00
12/07/16
15:00
Options
Western Digital calls active as shares surge »

Western Digital calls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCO

Columbus McKinnon

$27.59

1.07 (4.03%)

14:59
12/07/16
12/07
14:59
12/07/16
14:59
Downgrade
Columbus McKinnon rating change  »

Columbus McKinnon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

HON

Honeywell

$116.25

3.18 (2.81%)

14:58
12/07/16
12/07
14:58
12/07/16
14:58
Hot Stocks
Trian declines to comment as Honeywell hits high of day »

Nelson Peltz's Trian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

  • 16

    Dec

  • 10

    Jan

HRB

H&R Block

$23.42

0.73 (3.22%)

14:55
12/07/16
12/07
14:55
12/07/16
14:55
Technical Analysis
H&R Block technical comments ahead of earnings news »

The shares have been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

APO

Apollo Global

$19.99

0.71 (3.68%)

, CS

Credit Suisse

$15.46

0.77 (5.24%)

14:54
12/07/16
12/07
14:54
12/07/16
14:54
Periodicals
Apollo-backed Warrior working with lenders on IPO for next year, Bloomberg says »

Apollo Global…

APO

Apollo Global

$19.99

0.71 (3.68%)

CS

Credit Suisse

$15.46

0.77 (5.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 14

    Dec

14:50
12/07/16
12/07
14:50
12/07/16
14:50
General news
Canada Capacity Utilization Preview »

Canada Capacity…

LULU

lululemon

$57.24

0.12 (0.21%)

14:49
12/07/16
12/07
14:49
12/07/16
14:49
Options
lululemon options imply 14.0% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Jan

14:45
12/07/16
12/07
14:45
12/07/16
14:45
General news
Canada Housing Starts Preview »

Canada Housing Starts…

14:45
12/07/16
12/07
14:45
12/07/16
14:45
General news
Consumer Credit to be reported at 15:00 »

October Consumer Credit…

14:45
12/07/16
12/07
14:45
12/07/16
14:45
General news
Breaking General news story  »

November Treasury STRIPS…

ATSG

Air Transport Services

$16.32

0.02 (0.12%)

14:42
12/07/16
12/07
14:42
12/07/16
14:42
Hot Stocks
Air Transport Services says preliminary injunction granted in labor matter »

Air Transport Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$190.01

-0.935 (-0.49%)

14:42
12/07/16
12/07
14:42
12/07/16
14:42
Hot Stocks
Allergan CEO: Drug industry should self-regulate pricing »

Allergan CEO Brent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

COST

Costco

$151.01

-0.76 (-0.50%)

, HRB

H&R Block

$23.44

0.75 (3.31%)

14:40
12/07/16
12/07
14:40
12/07/16
14:40
Earnings
Notable companies reporting after market close »

Notable companies…

COST

Costco

$151.01

-0.76 (-0.50%)

HRB

H&R Block

$23.44

0.75 (3.31%)

LULU

lululemon

$57.24

0.12 (0.21%)

CAS

A. M. Castle

UNFI

United Natural Foods

$48.66

-0.7 (-1.42%)

VRNT

Verint

$38.20

0.15 (0.39%)

OLLI

Ollie's Bargain Outlet

$31.50

0.05 (0.16%)

TLRD

Tailored Brands

$18.89

0.58 (3.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

  • 08

    Dec

  • 13

    Dec

  • 15

    Dec

  • 09

    Jan

  • 09

    Jan

HLT

Hilton

$26.81

0.495 (1.88%)

14:40
12/07/16
12/07
14:40
12/07/16
14:40
Options
Heightened call activity in Hilton everyday so far in December »

Heightened call activity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

TST

TheStreet

14:36
12/07/16
12/07
14:36
12/07/16
14:36
Initiation
TheStreet initiated  »

TheStreet initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SYK

Stryker

$112.97

0.38 (0.34%)

14:34
12/07/16
12/07
14:34
12/07/16
14:34
Hot Stocks
Stryker raises quarterly dividend to 42.5c per share »

Stryker announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

VNCE

Vince Holding

$4.28

0.075 (1.79%)

14:30
12/07/16
12/07
14:30
12/07/16
14:30
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Jan

CMA

Comerica

$67.49

-0.2 (-0.30%)

14:30
12/07/16
12/07
14:30
12/07/16
14:30
Periodicals
Comerica moves higher as company alleged to 'warm' to possible sale »

According to Benzinga, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

CX

CEMEX

$8.42

0.205 (2.50%)

14:25
12/07/16
12/07
14:25
12/07/16
14:25
Options
Cemex call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:25
12/07/16
12/07
14:25
12/07/16
14:25
Conference/Events
Senate Commerce, Science & Transportation Committee to hold a hearing »

The Subcommittee on…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.